In this episode, Marybeth speaks with Dr. Nathan Fowler, Chief Medical Officer of BostonGene and former Professor of Medicine at MD Anderson Cancer Center, about why biomarker testing is helping turn personalized medicine from an idea into a reality. They discuss what biomarker testing, tumor sequencing, liquid biopsy, and ctDNA actually mean, why this information can be critical to choosing the right treatment, and why too many patients still are not being tested.

Dr. Fowler explains why he believes biomarker testing should happen as early as possible, how patients can advocate for themselves, how tumor testing differs from inherited genetic testing, and when repeat testing may be needed. He also shares a remarkable story of a patient with advanced lymphoma whose biomarker matched an experimental therapy and led to a complete remission that has lasted more than a decade.

Topics discussed:

What biomarker-driven care actually means

Why tumor sequencing can change treatment decisions

The difference between tumor testing and genetic testing

When liquid biopsy and ctDNA may be useful

How biomarker testing can open clinical trial options

Why testing should happen earlier in cancer care

How BostonGene is using AI to improve precision oncology

If you found this valuable, LIKE, SUBSCRIBE, and SHARE to help others access life-saving information!

Facebook: https://www.facebook.com/outperformcancer/

LinkedIn: https://www.linkedin.com/company/outperform-cancer/

Instagram: https://www.instagram.com/marybethgilliam/

Threads: https://www.threads.com/@marybethgilliam